Preventive And Therapeutic Vaccines Market

By Type;

Therapeutic Vaccine and Preventive Vaccine

By Disease Type;

Autoimmune Disease, Neurological Disease, Cancer, and Infectious Disease

By Vaccine Type;

Allogeneic Vaccine and Autologous Vaccine

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn486848312 Published Date: June, 2025 Updated Date: July, 2025

Preventive And Therapeutic Vaccine Market Overview

Preventive And Therapeutic Vaccine Market (USD Million)

Preventive And Therapeutic Vaccine Market was valued at USD 54052.83 million in the year 2024. The size of this market is expected to increase to USD 92637.06 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.0%.


Preventive And Therapeutic Vaccines Market

*Market size in USD million

CAGR 8.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)8.0 %
Market Size (2024)USD 54052.83 Million
Market Size (2031)USD 92637.06 Million
Market ConcentrationMedium
Report Pages366
54052.83
2024
92637.06
2031

Major Players

  • Sanofi Pasteur
  • Merck & Co
  • Pfizer
  • GlaxoSmithKline

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Preventive And Therapeutic Vaccines Market

Fragmented - Highly competitive market without dominant players


The Preventive And Therapeutic Vaccine Market is undergoing substantial growth, driven by heightened interest in both disease prevention and the treatment of complex conditions. More than 65% of healthcare frameworks now incorporate preventive vaccines into routine care, while therapeutic vaccines are rapidly gaining ground as a targeted solution for chronic illnesses. These trends offer vast opportunities for technological innovation and market expansion.

Innovations Enhancing Vaccine Technology
Emerging vaccine technologies are reshaping development pathways, with biotech-driven platforms such as mRNA accounting for over 58% of pipeline activity. These innovations are leading to higher vaccine efficiency and faster response times. Increased collaboration between pharmaceutical companies and tech startups is fueling a robust landscape for innovative breakthroughs and improved patient outcomes.

Advanced Vaccine Platforms Catalyzing Growth
Advanced modalities such as DNA-based and peptide vaccines now contribute to over 60% of market traction, driving the next wave of expansion. These platforms offer scalability, precision, and flexibility, particularly in addressing emerging health threats. With growing support from government initiatives and industry investment, these advancements are aligning with long-term growth objectives.

Innovation-Led Future for Immunization Solutions
A future shaped by customized therapies and AI-enabled vaccine discovery is redefining the market outlook. Over 68% of new R&D projects focus on novel vaccine targets, bridging the gap between preventive care and therapeutic treatment. This forward-looking approach not only supports strategic growth but also accelerates the delivery of impactful, patient-specific immunization solutions.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Disease Type
    3. Market Snapshot, By Vaccine Type
    4. Market Snapshot, By Region
  4. Preventive And Therapeutic Vaccine Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising awareness about preventive healthcare
        2. Introduction of new vaccines
        3. Government initiatives
      2. Restraints
        1. Vaccine hesitancy
        2. High cost of vaccines
        3. Stringent regulatory requirements
      3. Opportunities
        1. Development of vaccines for new diseases
        2. Focus on personalized vaccines
        3. Increased investment in R&D
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Preventive And Therapeutic Vaccine Market, By Type, 2021 - 2031 (USD Million)
      1. Therapeutic Vaccine
      2. Preventive Vaccine
    2. Preventive And Therapeutic Vaccine Market, By Disease Type, 2021 - 2031 (USD Million)
      1. Autoimmune Disease
      2. Neurological Disease
      3. Cancer
      4. Infectious Disease
    3. Preventive And Therapeutic Vaccine Market, By Vaccine Type, 2021 - 2031 (USD Million)
      1. Allogeneic Vaccine
      2. Autologous Vaccine
    4. Preventive And Therapeutic Vaccine Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sanofi Pasteur
      2. Merck & Co
      3. Pfizer
      4. GlaxoSmithKline
      5. Agenus Inc.
      6. Argos Therapeutic Inc.
      7. Astellas Pharma Inc.
      8. AstraZeneca PLC
      9. Celldex Therapeutic Inc.
      10. CSL Ltd.
  7. Analyst Views
  8. Future Outlook of the Market